Skip to Content

Iopromide Pregnancy and Breastfeeding Warnings

Iopromide is also known as: Ultravist

Iopromide Pregnancy Warnings

Iopromide has been assigned to pregnancy category B by the FDA. Animal studies have revealed evidence of embryolethality (possibly due to maternal toxicity) but have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. The manufacturer recommends that DRUG should only be used during pregnancy when the potential benefits outweigh the potential risks to the developing fetus.

See references

Iopromide Breastfeeding Warnings

There are no data on the excretion of iopromide into human milk. However, many injectable contrast agents are excreted unchanged in human milk. Although it has not been established that serious adverse reactions occur in nursing infants, caution should be exercised when intravascular contrast agents are administered to nursing women because of potential adverse reaction, and consideration should be given to temporarily discontinuing nursing.

See references

References for pregnancy information

  1. "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.

References for breastfeeding information

  1. "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.